Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients
Primary Purpose
Postoperative Nausea, Postoperative Nausea and Vomiting
Status
Completed
Phase
Phase 2
Locations
Brazil
Study Type
Interventional
Intervention
Olanzapine
Sponsored by
About this trial
This is an interventional prevention trial for Postoperative Nausea focused on measuring nausea and vomiting
Eligibility Criteria
Inclusion criteria:
- Patients submitted to medium and large surgeries in the thoracic or abdominal region (mastectomies, breast plastic, hysterectomies, annexectomies, gynecological pelvic surgeries, colectomies, rettosigmoidectomies) under general anesthesia
- Patients aged between 18 and 60 years
- Patients considered to be at high risk for PONV according to the Apfel scale (Apfel 3 or 4)
- Patients with a history of chemotherapy-induced nausea and vomiting.
Exclusion criteria:
- Pregnancy or Lactation
- Current use of typical anti-psychotic medications or atypical
- History of allergy to olanzapine
- Myocardial infarction or unstable angina in the 6 months prior to the day of surgery planning
- History of severe ventricular arrhythmia (eg, VT or VF)
- Heart Failure Class II or greater second NYHA
- Postural hypotension or vasovagal syncope in the 6 months prior to the day of surgery planning
- Narrow angle glaucoma
- Parkinson's disease
- Dementia
- Inability to swallow medicines
- QT interval history greater than 450ms or torsades de pointes
- Patient does not want to participate in the study
- Videolaparoscopy surgery
- Contraindication for neuraxial block
Sites / Locations
- Cancer Institute of the State of Sao Paulo - ICESP
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
olanzapine tablets
Starch tablets
Arm Description
PATIENT WILL TAKE OLANZAPINE 10 MG, 1 hour BEFORE SURGERY
PATIENT WILL TAKE PLACEBO 1 hour BEFORE SURGERY
Outcomes
Primary Outcome Measures
incidence of postoperative nausea and vomiting
nausea and vomiting/ retching (dichotomous variable)
Secondary Outcome Measures
incidence of side effects
side effects
incidence of side effects
side effects
incidence of side effects
side effects
incidence of postoperative nausea and vomiting
nausea and vomiting/ retching (dichotomous variable)
incidence of postoperative nausea and vomiting
nausea and vomiting/ retching (dichotomous variable)
incidence of postoperative nausea
nausea and vomiting/ retching (dichotomous variable)
incidence of postoperative nausea
nausea and vomiting/ retching (dichotomous variable)
incidence of postoperative nausea
nausea and vomiting/ retching (dichotomous variable)
incidence of postoperative vomiting/retching
vomiting/ retching (dichotomous variable)
incidence of postoperative vomiting/retching
vomiting/ retching (dichotomous variable)
incidence of postoperative vomiting/retching
vomiting/ retching (dichotomous variable)
incidence of severe PONV
This scale consists of four questions. Each question generates a different score. For the first question, if the patient vomited or retched three or more times, the final score was 50. Otherwise, the highest score from question 1 or question 2 was multiplied by the scores of question 3 and question 4, yielding the final value. When the score was ≥ 50, the symptom was considered clinically important.
incidence of severe PONV
This scale consists of four questions. Each question generates a different score. For the first question, if the patient vomited or retched three or more times, the final score was 50. Otherwise, the highest score from question 1 or question 2 was multiplied by the scores of question 3 and question 4, yielding the final value. When the score was ≥ 50, the symptom was considered clinically important.
incidence of severe PONV
This scale consists of four questions. Each question generates a different score. For the first question, if the patient vomited or retched three or more times, the final score was 50. Otherwise, the highest score from question 1 or question 2 was multiplied by the scores of question 3 and question 4, yielding the final value. When the score was ≥ 50, the symptom was considered clinically important.
incidence of nausea severity
mild, moderate, or severe
incidence of nausea severity
mild, moderate, or severe
incidence of nausea severity
mild, moderate, or severe
Full Information
NCT ID
NCT03631004
First Posted
August 11, 2018
Last Updated
January 11, 2022
Sponsor
Instituto do Cancer do Estado de São Paulo
1. Study Identification
Unique Protocol Identification Number
NCT03631004
Brief Title
Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients
Official Title
Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients
Study Type
Interventional
2. Study Status
Record Verification Date
December 2021
Overall Recruitment Status
Completed
Study Start Date
October 1, 2018 (Actual)
Primary Completion Date
February 10, 2021 (Actual)
Study Completion Date
February 10, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Instituto do Cancer do Estado de São Paulo
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Olanzapine has been used as prophylactic antiemetic for chemotherapy induced nausea and vomiting.
The project aims to evaluate the efficacy of olanzapine in combination with ondansetron and dexamethasone in patients at high risk of postoperative nausea and vomiting, with previous history of nausea and vomiting induced by prior chemotherapy, submitted to medium and large surgery.
Detailed Description
Double blinded randomized clinical trial. Fifty patients will be selected for each group. Group A will receive 10mg olanzapine in the preoperative and group B will receive placebo in the preoperative period. Both groups will receive intravenous general anesthesia combined with epidural. All patients will receive epidural PCA.
The primary outcome of this study is the incidence of post-operative nausea and vomiting. The power of analysis was based on the following parameters: type error I (α = 0.05), error II (β = 0.8), 95% confidence interval and hypothesis test two-tailed. Thus, 42 patients are indicated per group to obtain reduction of the incidence of nausea and / or vomiting of the population risk from 60% to 30%. The population will be composed of 100 patients because it is assumed that percentage of loss of 10% per group.
The statistical analysis will be performed in program R version 3.5.1. The results obtained will be presented as mean + standard deviation for continuous data or absolute frequency for described data.
For quantitative variables, the Student's t-test will be used for with normal distribution or Mann-Whitney for non-distributed data normal.
For qualitative variables, the chi-square test will be used or Fisher's exact test. Significant difference is defined as p, 0.05.
Data will be collected and managed using REDCap data capture tools
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Nausea, Postoperative Nausea and Vomiting
Keywords
nausea and vomiting
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
olanzapine tablets
Arm Type
Experimental
Arm Description
PATIENT WILL TAKE OLANZAPINE 10 MG, 1 hour BEFORE SURGERY
Arm Title
Starch tablets
Arm Type
Placebo Comparator
Arm Description
PATIENT WILL TAKE PLACEBO 1 hour BEFORE SURGERY
Intervention Type
Drug
Intervention Name(s)
Olanzapine
Other Intervention Name(s)
Treatment
Intervention Description
olanzapine 10 mg is given before surgery
Primary Outcome Measure Information:
Title
incidence of postoperative nausea and vomiting
Description
nausea and vomiting/ retching (dichotomous variable)
Time Frame
0-24 hours
Secondary Outcome Measure Information:
Title
incidence of side effects
Description
side effects
Time Frame
0-6 hours
Title
incidence of side effects
Description
side effects
Time Frame
0-24 hours
Title
incidence of side effects
Description
side effects
Time Frame
24-48 hours
Title
incidence of postoperative nausea and vomiting
Description
nausea and vomiting/ retching (dichotomous variable)
Time Frame
0-6 hours
Title
incidence of postoperative nausea and vomiting
Description
nausea and vomiting/ retching (dichotomous variable)
Time Frame
24-48 hours
Title
incidence of postoperative nausea
Description
nausea and vomiting/ retching (dichotomous variable)
Time Frame
0-6 hours
Title
incidence of postoperative nausea
Description
nausea and vomiting/ retching (dichotomous variable)
Time Frame
0-24 hours
Title
incidence of postoperative nausea
Description
nausea and vomiting/ retching (dichotomous variable)
Time Frame
24-48 hours
Title
incidence of postoperative vomiting/retching
Description
vomiting/ retching (dichotomous variable)
Time Frame
0-6 hours
Title
incidence of postoperative vomiting/retching
Description
vomiting/ retching (dichotomous variable)
Time Frame
0-24 hours
Title
incidence of postoperative vomiting/retching
Description
vomiting/ retching (dichotomous variable)
Time Frame
24-48 hours
Title
incidence of severe PONV
Description
This scale consists of four questions. Each question generates a different score. For the first question, if the patient vomited or retched three or more times, the final score was 50. Otherwise, the highest score from question 1 or question 2 was multiplied by the scores of question 3 and question 4, yielding the final value. When the score was ≥ 50, the symptom was considered clinically important.
Time Frame
0-6 hours
Title
incidence of severe PONV
Description
This scale consists of four questions. Each question generates a different score. For the first question, if the patient vomited or retched three or more times, the final score was 50. Otherwise, the highest score from question 1 or question 2 was multiplied by the scores of question 3 and question 4, yielding the final value. When the score was ≥ 50, the symptom was considered clinically important.
Time Frame
0-24 hours
Title
incidence of severe PONV
Description
This scale consists of four questions. Each question generates a different score. For the first question, if the patient vomited or retched three or more times, the final score was 50. Otherwise, the highest score from question 1 or question 2 was multiplied by the scores of question 3 and question 4, yielding the final value. When the score was ≥ 50, the symptom was considered clinically important.
Time Frame
24-48 hours
Title
incidence of nausea severity
Description
mild, moderate, or severe
Time Frame
0-6 hours
Title
incidence of nausea severity
Description
mild, moderate, or severe
Time Frame
0-24 hours
Title
incidence of nausea severity
Description
mild, moderate, or severe
Time Frame
24-48 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Patients submitted to medium and large surgeries in the thoracic or abdominal region (mastectomies, breast plastic, hysterectomies, annexectomies, gynecological pelvic surgeries, colectomies, rettosigmoidectomies) under general anesthesia
Patients aged between 18 and 60 years
Patients considered to be at high risk for PONV according to the Apfel scale (Apfel 3 or 4)
Patients with a history of chemotherapy-induced nausea and vomiting.
Exclusion criteria:
Pregnancy or Lactation
Current use of typical anti-psychotic medications or atypical
History of allergy to olanzapine
Myocardial infarction or unstable angina in the 6 months prior to the day of surgery planning
History of severe ventricular arrhythmia (eg, VT or VF)
Heart Failure Class II or greater second NYHA
Postural hypotension or vasovagal syncope in the 6 months prior to the day of surgery planning
Narrow angle glaucoma
Parkinson's disease
Dementia
Inability to swallow medicines
QT interval history greater than 450ms or torsades de pointes
Patient does not want to participate in the study
Videolaparoscopy surgery
Contraindication for neuraxial block
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Roger Chammas
Organizational Affiliation
Instituto do Cancer do Estado de São Paulo
Official's Role
Study Director
Facility Information:
Facility Name
Cancer Institute of the State of Sao Paulo - ICESP
City
Sao Paulo
State/Province
São Paulo
ZIP/Postal Code
01403010
Country
Brazil
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients
We'll reach out to this number within 24 hrs